DUBLIN, April 26, 2011 /PRNewswire-FirstCall/ -- Shire plc (LSE: SHP, NASDAQ: SHPGY), the global specialty biopharmaceutical company (the "Company") announces that at its Annual General Meeting today, all resolutions contained in the notice of meeting were duly passed and the results of the poll are as follows:
For* Against Withheld**
1. To receive the 434,920,990 99.46% 2,344,010 0.54% 1,047,773
Company's accounts
together with the
Directors' and
Auditors' reports
2. To approve the 371,352,068 85.39% 63,551,261 14.61% 3,409,444
Directors'
remuneration
report
3. To re-elect 417,978,353 95.95% 17,628,440 4.05% 2,705,980
Matthew Emmens as
a Director of the
Company
4. To re-elect Angus 435,218,771 99.61% 1,698,734 0.39% 1,395,268
Russell as a
Director of the
Company
5. To re-elect Graham 435,152,221 99.60% 1,764,913 0.40% 1,395,639
Hetherington as a
Director of the
Company
6. To re-elect David 436,960,582 99.92% 358,052 0.08% 994,139
Kappler as a
Director of the
Company
7. To re-elect 435,708,499 99.63% 1,614,018 0.37% 990,256
Patrick Langlois
as a Director of
the Company
8. To re-elect Dr 434,370,246 99.37% 2,740,035 0.63% 1,202,492
Jeffrey Leiden as
a Director of the
Company
9. To elect Dr David 436,960,853 99.92% 353,430 0.08% 998,490
Ginsburg as a
Director of the
Company
10. To elect Anne 436,387,198 99.79% 930,666 0.21% 994,909
Minto as a
Director of the
Company
11. To re-appoint 436,552,369 99.82% 773,722 0.18% 986,682
Deloitte LLP as
Auditors of the
Company
12. To authorize the 436,986,474 99.97% 139,910 0.03% 1,186,389
Audit, Compliance
& Risk Committee
to determine the
remuneration of
the Auditors
13. To authorize the 389,393,127 90.24% 42,136,878 9.76% 6,782,768
allotment of
shares
14. To authorize the 436,331,828 99.81% 812,978 0.19% 1,167,967
disapplication of
pre-emption rights
15. To authorize 435,373,076 99.58% 1,834,752 0.42% 1,104,945
market purchases
16. To adopt new 434,712,537 99.84% 702,963 0.16% 2,897,273
Articles of
Association
17. To approve the 378,440,959 86.57% 58,704,213 13.43% 1,167,601
notice of period
for general
meetings
* These figures include discretionary votes
** A vote "withheld" is not a vote in law and is not counted in the calculation of the votes "for" or "against" a resolution.
As at the record date, April 24, 2011, there were 562,246,293 ordinary shares in issue. Shareholders are entitled to one vote per share.
In accordance with Listing Rule 9.6.2 copies of the resolutions passed at the meeting have been submitted to the National Storage Mechanism and will be available for viewing shortly at: http://www.hemscott/nsm.do.
Notes to editors
SHIRE PLC
Shire's strategic goal is to become the leading specialty biopharmaceutical company that focuses on meeting the needs of the specialist physician. Shire focuses its business on attention deficit hyperactivity disorder (ADHD), human genetic therapies (HGT) and gastrointestinal (GI) diseases as well as opportunities in other therapeutic areas to the extent they arise through acquisitions. Shire's in-licensing, merger and acquisition efforts are focused on products in specialist markets with strong intellectual property protection and global rights. Shire believes that a carefully selected and balanced portfolio of products with strategically aligned and relatively small-scale sales forces will deliver strong results.
For further information on Shire, please visit the Company's website: http://www.shire.com.
For further information please contact:
Investor Eric Rojas ([email protected]) +1-781-482-0999
Relations
Sarah Elton-Farr ([email protected]) +44-1256-894157
Media Jessica Mann ([email protected]) +44-1256-894-280
SOURCE Shire plc
Share this article